TERNS PHARMACEUTICALS INC's ticker is TERN and the CUSIP is 880881107. A total of 66 filers reported holding TERNS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,304,259 | +158.0% | 259,296 | +348.7% | 0.00% | – |
| Q2 2023 | $505,593 | -52.2% | 57,782 | -35.3% | 0.00% | – |
| Q1 2023 | $1,057,359 | +859.1% | 89,304 | +724.6% | 0.00% | – |
| Q4 2022 | $110,249 | +57.5% | 10,830 | -9.1% | 0.00% | – |
| Q3 2022 | $70,000 | +70.7% | 11,916 | -28.2% | 0.00% | – |
| Q2 2022 | $41,000 | -16.3% | 16,588 | +1.0% | 0.00% | – |
| Q1 2022 | $49,000 | -54.6% | 16,427 | +8.0% | 0.00% | – |
| Q4 2021 | $108,000 | – | 15,208 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,099,309 | $13,015,819 | 9.59% |
| VR Adviser, LLC | 3,619,522 | $42,855,140 | 8.37% |
| Vivo Capital, LLC | 6,657,992 | $78,830,625 | 5.47% |
| Fairmount Funds Management LLC | 2,040,000 | $24,153,600 | 4.15% |
| Decheng Capital Management III (Cayman), LLC | 714,285 | $8,457,134 | 3.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 667,922 | $7,908,196 | 3.26% |
| Ikarian Capital, LLC | 721,341 | $8,540,677 | 1.94% |
| Orbimed Advisors | 7,619,135 | $90,210,558 | 1.77% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,448,275 | $40,827,576 | 1.72% |
| CROSSPOINT FINANCIAL, LLC | 12,054 | $142,719 | 1.54% |